Silencing of KCNA1 Suppresses the Cervical Cancer Development Via Mitochondria Damage

Overview

Journal Channels (Austin)

Specialty Biochemistry

Date 2019 Jul 30

PMID 31354026

Citations 18

Authors

Li Liu

Yumei Chen

Qingyuan Zhang

Changzhong Li

Affiliations

Soon will be listed here.

Abstract

Voltage-gated potassium channel subfamily A member 1 (KCNA1/Kv1.1) is an important component of type A potassium channels, which has been found to be involved in various tumors. This study aimed to identify the role of KCNA1 in cervical cancer and explore the related mechanism. The levels of KCNA1 in cervical cancer tissues and cell lines were examined by Western blot and qPCR. Cell proliferation and invasion were assessed by CCK-8 and transwell assays, respectively. Protein levels of Hedgehog (Hhg), Wnt and Notch were detected by Western blot. The mitochondrial capacity was examined by immunostaining with MitoTracker Red CMXRos. KCNA1 was highly expressed in cervical cancer tissues and cell lines, and correlated with poor prognosis. In addition, depletion of KCNA1 suppressed growth, proliferation, migration and invasion of HeLa cells. Moreover, KCNA1 could regulate the Hhg, Wnt and Notch signaling pathways and cause mitochondrial dysfunction. The present study has demonstrated that KCNA1 is an oncogene excessively expressed in cervical cancer, and promotes tumor progression by regulating the Hhg, Wnt and Notch signaling pathways and the mitochondrial capacity. Therefore, our results provide a theoretical basis for the discovery of novel clinical treatment against cervical cancer.

Citing Articles

Transcriptional regulation of KCNA2 coding Kv1.2 by EWS::FLI1: involvement in controlling the YAP/Hippo signalling pathway and cell proliferation.

Dupuy M, Postec A, Mullard M, Chantome A, Hulin P, Brion R Cell Commun Signal. 2024; 22(1):602.

PMID: 39695664 PMC: 11657695. DOI: 10.1186/s12964-024-01981-4.

A Molecular Signature of the Ubiquitin-Proteasome System for Forecasting Prognosis in Thyroid Carcinoma Patients.

Zeng H, Geng X, Wan H, Qu X, Tang S, Zhang R J Inflamm Res. 2024; 17:10397-10419.

PMID: 39654864 PMC: 11627108. DOI: 10.2147/JIR.S499820.

Micro- and Macronutrients in Endometrial Cancer-From Metallomic Analysis to Improvements in Treatment Strategies.

Hunek G, Zembala J, Januszewski J, Belzek A, Syty K, Jabiry-Zieniewicz Z Int J Mol Sci. 2024; 25(18).

PMID: 39337406 PMC: 11432114. DOI: 10.3390/ijms25189918.

Mitochondrial protein isoleucyl-tRNA synthetase 2 in tumor cells as a potential therapeutic target for cervical cancer.

Meng X, Gao B, Li N Cytojournal. 2024; 21:22.

PMID: 38989294 PMC: 11234349. DOI: 10.25259/Cytojournal_17_2024.

Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity.

Quagliariello V, Canale M, Bisceglia I, Iovine M, Paccone A, Maurea C Front Cardiovasc Med. 2024; 11:1289663.

PMID: 38818214 PMC: 11138344. DOI: 10.3389/fcvm.2024.1289663.

References

Grjibovski A, Dubovichenko D, Saduakassova S, Zhatkanbayeva G, Omarova G, Shalgumbayeva G . Incidence, mortality and determinants of survival from cervical cancer in Northwest Russia: a registry-based cohort study. Int Health. 2018; 10(2):92-99. DOI: 10.1093/inthealth/ihx068. View

van der Bliek A, Sedensky M, Morgan P . Cell Biology of the Mitochondrion. Genetics. 2017; 207(3):843-871. PMC: 5676242. DOI: 10.1534/genetics.117.300262. View

Zhang Y, Guo X, Wang G, Ma W, Liu R, Han X . Real-World Study of the Incidence, Risk Factors, and Prognostic Factors Associated with Bone Metastases in Women with Uterine Cervical Cancer Using Surveillance, Epidemiology, and End Results (SEER) Data Analysis. Med Sci Monit. 2018; 24:6387-6397. PMC: 6146765. DOI: 10.12659/MSM.912071. View

Tsai H, Baylin S . Cancer epigenetics: linking basic biology to clinical medicine. Cell Res. 2011; 21(3):502-17. PMC: 3193419. DOI: 10.1038/cr.2011.24. View

Samarzija I, Beard P . Hedgehog pathway regulators influence cervical cancer cell proliferation, survival and migration. Biochem Biophys Res Commun. 2012; 425(1):64-9. DOI: 10.1016/j.bbrc.2012.07.051. View

Lassche S, Lainez S, Bloem B, van de Warrenburg B, Hofmeijer J, Lemmink H . A novel KCNA1 mutation causing episodic ataxia type I. Muscle Nerve. 2014; 50(2):289-91. DOI: 10.1002/mus.24242. View

Sharma A, De R, Javed S, Srinivasan R, Pal A, Bhattacharyya S . Sonic hedgehog pathway activation regulates cervical cancer stem cell characteristics during epithelial to mesenchymal transition. J Cell Physiol. 2019; 234(9):15726-15741. DOI: 10.1002/jcp.28231. View

Mariani A, Wang C, Oberg A, Riska S, Torres M, Kumka J . Genes associated with bowel metastases in ovarian cancer. Gynecol Oncol. 2019; 154(3):495-504. PMC: 8767766. DOI: 10.1016/j.ygyno.2019.06.010. View

Lallet-Daher H, Wiel C, Gitenay D, Navaratnam N, Augert A, Le Calve B . Potassium channel KCNA1 modulates oncogene-induced senescence and transformation. Cancer Res. 2013; 73(16):5253-65. DOI: 10.1158/0008-5472.CAN-12-3690. View

10.

Arbyn M, Walker A, Meijer C . HPV-based cervical-cancer screening in China. Lancet Oncol. 2010; 11(12):1112-3. DOI: 10.1016/S1470-2045(10)70262-X. View

11.

Stumbar S, Stevens M, Feld Z . Cervical Cancer and Its Precursors: A Preventative Approach to Screening, Diagnosis, and Management. Prim Care. 2019; 46(1):117-134. DOI: 10.1016/j.pop.2018.10.011. View

12.

Yin X, Lin J, Cao L, Zhang T, Zeng S, Zhang K . Familial paroxysmal kinesigenic dyskinesia is associated with mutations in the KCNA1 gene. Hum Mol Genet. 2018; 27(4):625-637. DOI: 10.1093/hmg/ddx430. View

13.

Cui Q, Wen S, Huang P . Targeting cancer cell mitochondria as a therapeutic approach: recent updates. Future Med Chem. 2017; 9(9):929-949. DOI: 10.4155/fmc-2017-0011. View

14.

Bateman L, Blakemore S, Koneru A, Mtesigwa T, McCree R, Lisovicz N . Barriers and Facilitators to Cervical Cancer Screening, Diagnosis, Follow-Up Care and Treatment: Perspectives of Human Immunodeficiency Virus-Positive Women and Health Care Practitioners in Tanzania. Oncologist. 2018; 24(1):69-75. PMC: 6324638. DOI: 10.1634/theoncologist.2017-0444. View

15.

Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C . The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 2005; 439(7078):871-4. DOI: 10.1038/nature04431. View

16.

Dong L, Neuzil J . Mitochondria in cancer: why mitochondria are a good target for cancer therapy. Prog Mol Biol Transl Sci. 2014; 127:211-27. DOI: 10.1016/B978-0-12-394625-6.00008-8. View

17.

Huang L, Li B, Tang S, Guo H, Li W, Huang X . Mitochondrial KATP Channels Control Glioma Radioresistance by Regulating ROS-Induced ERK Activation. Mol Neurobiol. 2014; 52(1):626-37. DOI: 10.1007/s12035-014-8888-1. View

18.

Dong J, Su M, Chang W, Zhang K, Wu S, Xu T . Long non-coding RNAs on the stage of cervical cancer (Review). Oncol Rep. 2017; 38(4):1923-1931. DOI: 10.3892/or.2017.5905. View

19.

Ballestar E, Esteller M . Epigenetic gene regulation in cancer. Adv Genet. 2008; 61:247-67. DOI: 10.1016/S0065-2660(07)00009-0. View

20.

van der Wijst J, Konrad M, Verkaart S, Tkaczyk M, Latta F, Altmuller J . A de novo KCNA1 Mutation in a Patient with Tetany and Hypomagnesemia. Nephron. 2018; 139(4):359-366. PMC: 6492638. DOI: 10.1159/000488954. View